IFP Advisors’s Neurogene NGNE Stock Holding History

IFP Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31	Hold	1	–	–	﹤0.01%	5050
2026 Q1	$20	Buy	+1	New	+$19	﹤0.01%	4922
2025 Q2	–	Hold	0	–	–	–	4536
2025 Q1	–	Hold	0	–	–	–	3989
2024 Q4	–	Hold	0	–	–	–	3980

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

IFP Advisors's NGNE Position: Q2 2026 in Review

IFP Advisors held its Neurogene (NGNE) position steady in Q2 2026 at 1 share worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #5050.

IFP Advisors first reported a position in NGNE in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

IFP Advisors held 1 share of Neurogene worth $31 as of Q2 2026.
IFP Advisors left its Neurogene share count unchanged in Q2 2026.
Neurogene made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5050 holding.
IFP Advisors first reported a position in Neurogene in Q1 2026 and has held it in 2 quarters since.
112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.